Guided Therapeutics (GTHP) Research & Development (2010 - 2025)
Guided Therapeutics (GTHP) reported Research & Development of $323000.0 for Q4 2025, up 426.26% on a YoY basis from $61376.2 in Q4 2024, and up 137.5% sequentially from $136000.0 in Q3 2025.
Guided Therapeutics (GTHP) Research & Development (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of Research & Development data on file, last reported at $323000.0 in Q4 2025.
- For the quarter ending Q4 2025, Research & Development rose 426.26% year-over-year to $323000.0; the trailing twelve-month figure through Dec 2025 stood at $666000.0 (up 116.94% YoY), and the FY2025 full-year result was $469000.0, up 63.41% from the prior year.
- Research & Development advanced to $323000.0 in Q4 2025, from $136000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $323000.0 in Q4 2025 to a low of -$99000.0 in Q4 2024.
- A 5-year average of $72000.0 and a median of $67000.0 in 2023 frame the typical range for Research & Development.
- Across the five-year window, Research & Development soared 762.5% in 2023 and plunged 252.31% in 2024, its largest moves.
- Tracing GTHP's Research & Development over 5 years: stood at $89000.0 in 2021, then slumped by 158.43% to -$52000.0 in 2022, then jumped by 225.0% to $65000.0 in 2023, then sank by 252.31% to -$99000.0 in 2024, then jumped by 426.26% to $323000.0 in 2025.
- Business Quant data shows GTHP's Research & Development at $323000.0 in Q4 2025, $136000.0 in Q3 2025, and $133000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 767.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 413.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 671.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 516.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 263.30 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 145.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -461.27 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 345.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | 323,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 323,000.00 |
| Sep 30, 2025 | 136,000.00 |
| Jun 30, 2025 | 133,000.00 |
| Mar 31, 2025 | 74,000.00 |
| Dec 31, 2024 | -99,000.00 |
| Sep 30, 2024 | 111,000.00 |
| Jun 30, 2024 | 222,000.00 |
| Mar 31, 2024 | 73,000.00 |
| Dec 31, 2023 | 65,000.00 |
| Sep 30, 2023 | 69,000.00 |
| Jun 30, 2023 | 61,000.00 |
| Mar 31, 2023 | 73,000.00 |
| Dec 31, 2022 | -52,000.00 |
| Sep 30, 2022 | 8,000.00 |
| Jun 30, 2022 | 37,000.00 |
| Mar 31, 2022 | 40,000.00 |
| Dec 31, 2021 | 89,000.00 |
| Sep 30, 2021 | 41,000.00 |
| Jun 30, 2021 | 20,000.00 |
| Mar 31, 2021 | 16,000.00 |